BibbInstruments

BibbInstruments Financial Leverage

The Financial Leverage (Equity Multiplier) of BibbInstruments (BIBB.SL) as of Oct 20, 2026 is 1.07. In the previous year, Financial Leverage (Equity Multiplier) was 1.19 — a change of -10.11% (lower).

Financial Leverage

1.07

YoY

-10.11%

Last updated:

Financial Leverage (Equity Multiplier) of BibbInstruments is 2025 1.07 . Financial Leverage (Equity Multiplier) of BibbInstruments was 2024 1.19 . It decreases by -10.11% lower compared to the previous year.

The BibbInstruments Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2018
1.12 SEK
Jan 1, 2019
1.06 SEK
Jan 1, 2020
1.06 SEK
Jan 1, 2021
1.09 SEK
Jan 1, 2022
1.10 SEK
Jan 1, 2023
1.07 SEK
Jan 1, 2024
1.19 SEK
Jan 1, 2025
1.07 SEK
The BibbInstruments Financial Leverage history
YEARFinancial LeverageYoY
1.07-10.11%
1.19+11.25%
1.07-2.47%
1.10+0.48%
1.09+2.83%
1.06-0.37%
1.06-4.97%
1.12+3.43%
1.08-39.53%
1.79-27.85%
2.48+47.35%
1.68—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BibbInstruments Stock analysis

What does BibbInstruments do? BiBBInstruments AB generates revenue through the development and sale of diagnostic instruments for early cancer detection, primarily utilizing its EndoDrill technology platform. The company markets specific products including EndoDrill GI Upper for stomach biopsies, EndoDrill GI Lower for intestinal biopsies, EndoDrill GI Lung for lung biopsies, EndoDrill Therapy for organ displacement procedures, EndoDrill Needle for breast biopsies, and EndoDrill Model X for multiple applications. These instruments are sold to hospitals with endoscopy specialist centers and surgical wards, focusing on Scandinavian countries as their primary market. The company's portfolio targets medical professionals requiring precise diagnostic tools for deep skin tissue analysis and treatment procedures. The business model centers on selling specialized biopsy instruments that enable early cancer diagnosis in various organs. EndoDrill GI Upper, GI Lower, and GI Lung are designed for gastrointestinal and respiratory tract biopsies, while EndoDrill Therapy facilitates treatment procedures involving stents and conductors. EndoDrill Needle specifically addresses breast biopsy needs, and EndoDrill Model X serves as an independent research project covering multiple anatomical areas. All products are distributed through hospital networks specializing in endoscopy and surgery. BiBBInstruments AB's revenue streams are derived from direct sales of its diagnostic instrument portfolio to healthcare institutions. The company focuses on Scandinavian countries for distribution, targeting hospitals with specialized endoscopy centers and surgical departments. The EndoDrill technology platform underpins all products, providing a unified approach to early cancer detection and treatment procedures across different medical specialties. BibbInstruments is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BibbInstruments stock

Financial Leverage (Equity Multiplier) of BibbInstruments is 1.07 in 2025.

Financial Leverage (Equity Multiplier) of BibbInstruments changed from 1.19 to 1.07, representing a -10.11% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) BibbInstruments since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s BibbInstruments with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — BibbInstruments

All Key Metrics — BibbInstruments